摘要
随着组蛋白赖氨酸去甲基化酶的发现,证实组蛋白赖氨酸甲基化是一个可以逆转的组蛋白表遗传修饰。赖氨酸特异性组蛋白去甲基化酶1(lysinespecificdemethylase1,LSD1)是一个FAD依赖性胺氧化酶,它能够特异性脱去单甲基化和二甲基化H3K4和H3K9位点上的甲基基团。JmjC蛋白JHDM1、JHDM2、JMJD23个亚家族都具有组蛋白赖氨酸去甲基化酶活性。目前证实组蛋白甲基化与去甲基化失平衡与肿瘤发生相关。组蛋白赖氨酸去甲基化酶有可能成为一个新的抗肿瘤治疗靶标。
The discovery of the histone lysine demethylases has strongly demonstrated that histone lysine methylation is a reversible epigenetic modification. LSDI is a FAD-dependent amine oxidase and can specifically demethylate H3K4me2/mel and H3K9me2/mel. JmjC protein, including JHDMI, JHDM2 and JMJD2 subfamily, has been recently reported to have histone lysine demethylase activity. The imbalance of histone methylation has been linked to tumorigenesis. Therefore, histone lysine demethylases may serve as a new target for anti-cancer therapy.
出处
《医学分子生物学杂志》
CAS
CSCD
2006年第6期446-449,共4页
Journal of Medical Molecular Biology